Markets:

Overview

News

Currencies

International

Treasuries

ALX Oncology Holdings Inc. - Common Stock (NQ:ALXO)

1.430 -0.040 (-2.72%)

Streaming Delayed Price Updated: 11:34 AM EST, Jan 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ALX Oncology Holdings Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Bed Bath & Beyond Shares Are Trading Higher By 17%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

January 10, 2023

Gainers

Via Benzinga

Super Micro Computer, Rayonier Advanced Materials And Some Other Big Stocks Moving Lower On Tuesday ↗

January 10, 2023

U.S. stocks traded slightly higher, with the Dow Jones gaining around 30 points on Tuesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer ↗

January 28, 2022

The

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

January 10, 2023

Via Benzinga

ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2023

January 05, 2023

From ALX Oncology

Via GlobeNewswire

ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 03, 2023

From ALX Oncology

Via GlobeNewswire

AMC Preferred Equity Units, Accolade And Some Other Big Stocks Moving Higher On Friday ↗

December 23, 2022

U.S. stocks traded mixed, with the Dow Jones gaining over 50 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

ALX Oncology Announces Initial Data from ASPEN-05 Study of Evorpacept in Combination with Azacitidine and Venetoclax, Demonstrating Tolerability and Preliminary Activity in Patients with Acute Myeloid Leukemia

December 12, 2022

From ALX Oncology

Via GlobeNewswire

ALX Oncology Appoints Scott Garland to its Board of Directors

November 29, 2022

From ALX Oncology

Via GlobeNewswire

ALX Oncology Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

November 08, 2022

From ALX Oncology

Via GlobeNewswire

ALX Oncology to Present New Clinical Data on Evorpacept in Acute Myeloid Leukemia at 64th ASH Annual Meeting

November 03, 2022

From ALX Oncology

Via GlobeNewswire

ALX Oncology Announces Upcoming Investor Conference Participation

November 02, 2022

From ALX Oncology

Via GlobeNewswire

ALX Oncology Enters $100 Million Loan Facility Agreement with Oxford Finance and Silicon Valley Bank to Support Ongoing Development of Evorpacept

October 31, 2022

Expects to extend cash runway to mid-2025

From ALX Oncology

Via GlobeNewswire

ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

October 05, 2022

From ALX Oncology

Via GlobeNewswire

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary ↗

August 11, 2022

Via Benzinga

ALX Oncology Shares Climb As Mid-Stage Triple Combination Colorectal Cancer Study Kicks-off ↗

August 11, 2022

ALX Oncology Holdings (NASDAQ: ALXO) has initiated a Phase 2 investigator-sponsored study of evorpacept in combination with Eli Lilly’s (NYSE: LLY) ERBITUX (cetuximab) and Merck’s (NASDAQ:

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 01, 2022

Via Benzinga

Daily Biotech Pulse: Celyad Resumes Colorectal Cancer Trial, Setback For Otonomy, AstraZeneca Halts Phase 3 Head, Neck Cancer Trial ↗

August 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

ALX Oncology Shares Gain As FDA Grants Fast Track Status To Head And Neck Cancer Candidate ↗

August 01, 2022

ALX Oncology Holdings (NASDAQ: ALXO) receives Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead asset Evorpacept in combination with KEYTRUDA (pembrolizumab) for the...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

July 12, 2022

Gainers Guardant Health (NASDAQ:GH) stock rose 14.8% to $55.23 during Tuesday's after-market session. The market value of their outstanding shares is at $5.6 billion.

Via Benzinga

The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data ↗

June 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

ALX Oncology Shares Soar As FDA Grants Orphan Drug Status To Blood Cancer Candidate ↗

June 29, 2022

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ: ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

June 29, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

June 06, 2022

Monday's session saw 84 companies set new 52-week lows.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

May 31, 2022

On Tuesday, 36 companies achieved new lows for the year.

Via Benzinga

ALX Oncology Holdings: Q4 Earnings Insights ↗

February 28, 2022

ALX Oncology Holdings (NASDAQ:ALXO) reported its Q4 earnings results on Monday, February 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement...

Via Benzinga

The Daily Biotech Pulse: Biogen Liquidates Out Of Biosimilar JV, Provention Bio Plots Diabetes Drug Resubmission, Merck Finds COVID Pill Effective Against Omicron ↗

January 28, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

January 26, 2022

During Wednesday's morning session, 34 stocks hit new 52-week lows. Things to Consider About Today's 52-Week Lows: Illumina (NASDAQ:ILMN) was the biggest company...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

January 26, 2022

Gainers Vaccinex (NASDAQ:VCNX) shares moved upwards by 30.4% to $1.33 during Wednesday's pre-market session. The market value of their outstanding shares is at $40.9...

Via Benzinga

Gastrointestinal Cancer Treatment Trials Driven by Rising Incidences of Colorectal Cancer

January 20, 2022

Palm Beach, FL – January 20, 2022 – FinancialNewsMedia.com News Commentary – Despite significant progress in the treatment of gastric cancer, it is still among the leading causes of deaths due to...

Via FinancialNewsMedia

Topics Death

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.